Related Experiment Videos

The African-American heart failure trial: a new look at old drugs

G Michael Felker1

  • 1Duke Clinical Research Institute, 2400 Pratt St, Room 0311 Terrace Level, Durham, NC 27705, USA. Michael.felker@duke.edu

Future Cardiology
|October 7, 2009
PubMed

Insights

The African-American Heart Failure Trial (AHeFT) found that combining isosorbide dinitrate and hydralazine significantly reduced mortality by 43% in black patients with advanced heart failure.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Heart failure disproportionately affects African-American populations.
  • Existing treatments may have limited efficacy in specific demographic groups.
  • The combination of isosorbide dinitrate and hydralazine was investigated for potential benefits.

Purpose of the Study:

  • To evaluate the efficacy of a fixed-dose combination of isosorbide dinitrate and hydralazine in black patients with advanced heart failure.
  • To compare the combination therapy against a placebo in the target population.
  • To assess the impact on mortality, hospitalizations, and quality of life.

Main Methods:

  • The African-American Heart Failure Trial (AHeFT) was a randomized, placebo-controlled study.
  • Participants were black patients with advanced self-identified heart failure.
  • The study was terminated early due to observed significant benefits in the treatment arm.

Main Results:

  • A 43% reduction in all-cause mortality was observed in the group receiving isosorbide dinitrate and hydralazine.
  • Significant improvements were noted in hospitalizations for heart failure.
  • Enhanced quality of life was reported in the active treatment group.

Conclusions:

  • The combination of isosorbide dinitrate and hydralazine demonstrated a significant mortality benefit in black patients with advanced systolic heart failure.
  • The AHeFT study design offers a novel approach to clinical trials, considering drug mechanisms and patient pathophysiology.
  • Further research is needed to determine if these benefits extend to a broader heart failure population.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.